Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Mobocertinib
Takeda
Non-Small Cell Lung Cancer
1 trial -
Nimotuzumab and chemotherapy
Biotech Pharmaceutical Co.,
Non-small Cell Lung Cancer
1 trial -
Nivolumab
Iovance Biotherapeutics B.V.
Non-Small Cell Lung Cancer
1 trial -
PB-2018-V12
Chongqing Precision Biotech Co., Ltd
Non-small Cell Lung Cancer
1 trial -
PDR001
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
1 trial -
PEGylated recombinant human hyaluronidase PH20
HALOZYME THERAPEUTICS, INC.
Non-small Cell Lung Cancer
1 trial -
RMC-5127
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
RMC-6291
Revolution Medicines
Non-Small Cell Lung Cancer (NSCLC)
2 trials -
RMC-9805
Revolution Medicines
Non-small Cell Lung Cancer (NSCLC)
1 trial -
[14C]TGRX-326
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Enhanced dermatologic management
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Sequential Icotinib Plus Chemotherapy
Betta Pharmaceuticals Co.,
EGFR Positive Non-small Cell Lung Cancer
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Combination of chemotherapy and immunotherapy
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Hypervision proton surgery
Hospital Authority, Hong Kong
Non-Small Cell Lung Cancer
1 trial -
MR/PET
Hospital Authority, Hong Kong
Non-small Cell Lung Cancer
1 trial -
Paclitaxel Oral Solution
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small-Cell Lung Cancer
1 trial -
RNAseq
Takeda
Non-small Cell Lung Cancer
1 trial -
radiochemotherapy 1
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.